1990–94, after the diagnosis of OI, one-year survival probability is only 59.8% (95% CI 52.0–67.7%). The most common OI's are tuberculosis (40–50%), cryptococcosis (25–40%), *Pneumocystis carinii* pneumonia PCP (10–20%), toxoplasmosis (5–10%) and salmonellosis (5–10%). In the northern part of Thailand, where *Penicillium marneffei* is endemic, this infection is as common as tuberculosis, indicating the importance of local endemic infection to be recognized as AIDS-defining illnesses. Cryptococcosis carries the worst prognosis with 1-year survival probability of 31.9% (16.8–48.1%).
Since HAART became available and financially supported by Thai Government in 2001, the morbidity and mortality of HIV-infected persons have decreased remarkably. OI's has decreased and people living with AIDS/HIV survive much longer. The emergence of drug-resistant HIV has posed problems since the second line drugs are much more expensive and not many to choose from. In addition, this group can transmit drug-resistant HIV causing primary drug-resistant HIV infection which will make it more difficult to choose the proper regimen without genotyping the virus. Thus, strong prevention and control program should remain at top priority, to stop new infection and transmission.

I-24 HIV-specific T-cell responses in a cohort of slow progressors in China

T. Dong*. *WIMM, Oxford University, United Kingdom*

Background: There is an urgent need for an effective vaccine to prevent HIV-1 infection, and current efforts are directed towards generating vaccine candidates that will elicit a T-cell immune response to the virus.. No studies to date have described mechanisms of HIV resistance or delayed disease progression in Chinese cohorts. For both the design and the evaluation of CTL-inducing vaccines it is important to define immunodominant CTL epitopes for both the prevailing HLA types and the most common viral strains affecting that population. Morever, it is also important to identify composite features of T-cell responses associated with good outcome and T-cell epitopes that will generate such beneficial features.
Study cohort: Current studies are limited by the facts that most of the study cohort subjects have been infected for different lengths of time; infected with different viral strains and have a diverse genetic background. In this study, we have access to a unique village cohort of patients (N = 407) who were involved in a plasma donation scheme that became contaminated with clade B HIV-1 in the period 1994–1995. 137 premature adult deaths were recorded in the village with symptoms compatible with HIV-1 disease before 2003. Of the surviving patients, none were treated before 2003: therefore the proportion of slow or non-progressors is unusually high in this cohort (>50% had CD4 counts >200 in 2004).
Results: We found that HLA-A30 and B51 were strongly associated with low viral load in this cohort. We investigated the hypothesis that immunodominant T-cell responses to conserved HIV-1 proteins restricted by these alleles could be partially responsible for good control of virus. We used ELISPOT assays to test for responses to overlapping Clade B peptides spanning the whole viral proteome and to the 202 best characterised optimal epitopes from the Los Alamos data base. We found broad T cell responses, especially directed towards the gag protein, in patients with low viral loads. The immunodominance hierarchy of epitopes restricted by common HLA molecules in the cohort showed very different patterns from a published acute cohort (Altfeld, 2006). We have sequenced the gag and nef genes from 97 patients and will present data to show that the loss of certain responses in the chronic phase of infection might be due to early selection of escape mutants.
Conclusion: We have identified a panel of immunodominant T-cell responses restricted by common HLA alleles in a Chinese slow progressor cohort. Identification of the most beneficial responses will be particular important for future vaccine design targeted to the Chinese population.

I-25 Outcomes and challenges of the China National Free Antiretroviral Treatment Program

F.J. Zhang*. *National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China*

To combat the HIV/AIDS epidemic in China, the National Center for AIDS/STD Control and Prevention established the Division of Treatment and Care in late 2001. The pilot for the National Free ART Program began in Henan Province in 2002, and the program fully launched in 2003. Initially, treatment efforts focused on patients infected through illicit blood and plasma donations in the mid-1990s, and subsequently expanded to include HIV-infected injection drug users, commercial sex workers, pregnant women, and children. The National Free ART Database was established in late 2004, and includes data on current patients and those who were treated before 2004. Over 50,000 adult and pediatric patients have been treated thus far. Challenges for the program include integration of drug treatment services with ART, an under-resourced health care system, co-infections, stigma, discrimination, drug resistance, and procurement of second-line ART. The merging of national treatment and care, epidemiologic, and drug resistance databases will be critical for a better understanding of the epidemic, earlier identification of patients requiring ART, and improved patient follow-up. The Free ART Program has made considerable progress in providing the necessary care and treatment for HIV-infected people in China and has strong government support for continued improvement and expansion.

Concurrent Session 4 – Immunology and Virology

I-26 Immunology of HBV infection

J.M. Vierling*. *Professor of Medicine and Surgery, Chief of Hepatology, Baylor College of Medicine, Houston, TX, USA*

HBV is an enveloped, hepatotrophic, oncogenic hepadnavirus that infects hepatocytes and leukocytes of humans and chimpanzees. The clinicopathological outcomes of HBV infection are determined by both viral and host factors. HBV infects hepatocytes without triggering apoptosis, altering hepatocyte gene expression or inducing innate immune production of IFNα or IFNβ. Host determinants of outcomes are the quality, quantity, kinetics and immunoregulation of the integrated innate and adaptive immune responses. HBV subverts the innate immune response by down-regulating (1) expression of MICA, the primary ligand for the NKG2D receptors of NK cells and (2) TLR1, 2, 4 and 6 transcripts in PBMC. In addition, HBV persistence and disease progression is favored by the low production of mannose binding lectin (MBL) and reduction in the interferon-inducible APOBEC3 family of cytidine deaminases that inhibit HBV replication and hypermutate the HBV genome. Generation of polyclonal, multi-antigen-specific CD4 T-cell and CD8 cytotoxic T lymphocytes (CTL) is required for resolution of acute HBV infection through the combined effects of HBV-specific cytolysis of infected